Results 41 to 50 of about 704 (128)

The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. [PDF]

, 2017
Global tuberculosis incidence has declined marginally over the past decade, and tuberculosis remains out of control in several parts of the world including Africa and Asia.
Atre, Sachin R, Chang, Kwok Chiu, Churchyard, Gavin J, Clark, Taane G, Dheda, Keertan, Dooley, Kelly E, Dowdy, David, Esmail, Aliasgar, Fennelly, Kevin P, Furin, Jennifer, Goemaere, Eric, Gumbo, Tawanda, Hesseling, Anneke C, Horsburgh, C Robert, Jara, Carolina Morán, Jaramillo, Ernesto, Lange, Christoph, Lessem, Erica, Lin, Hsien-Ho, London, Leslie, Low, Marcus, Maartens, Gary, McIlleron, Helen, McNerney, Ruth, Menzies, Dick, Merker, Matthias, Murray, Megan, Nahid, Payam, Nardell, Edward A, Niemann, Stefan, Nuermberger, Eric, Padayatchi, Nesri, Pasipanodya, Jotam G, Rodrigues, Camilla, Schaaf, H Simon, Sirgel, Frik A, Siu, Gilman KH, Theron, Grant, Udwadia, Zarir F, van Helden, Paul, Van Rie, Annelies, Warren, Robin M   +41 more
core   +1 more source

TB and HIV Therapeutics: Pharmacology Research Priorities

AIDS Research and Treatment, Volume 2012, Issue 1, 2012., 2012
An unprecedented number of investigational drugs are in the development pipeline for the treatment of tuberculosis. Among patients with tuberculosis, co‐infection with HIV is common, and concurrent treatment of tuberculosis and HIV is now the standard of care.
Kelly E. Dooley, Peter S. Kim, Sharon D. Williams, Richard Hafner, Gary Maartens   +4 more
wiley   +1 more source

Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis

Disease Models & Mechanisms, 2015
Mice are the most commonly used species for non-clinical evaluations of drug efficacy against tuberculosis (TB). Unlike commonly used strains, C3HeB/FeJ mice develop caseous necrosis in the lung, which might alter the representation of drug efficacy in a
Jean-Philippe Lanoix, Anne J. Lenaerts, Eric L. Nuermberger   +2 more
doaj   +1 more source

Antimicrobial peptides as novel anti-tuberculosis therapeutics [PDF]

, 2016
"Available online 24 May 2016"Tuberculosis (TB), a disease caused by the human pathogen Mycobacterium tuberculosis, has recently joined HIV/AIDS as the world's deadliest infectious disease, affecting around 9.6 million people worldwide in 2014. Of those,
Agerberth, Ahsan, Andersson, Andersson, Andries, Aoki, Asaduzzaman, Balasubramanian, Bartolomeo, Bauer, Bayer, Bell, Bierbaum, Blaas, Bogatcheva, Bottger, Bray, Brogden, Brown, Brötz, Butler, Carroll, Center for Drug Evaluation and Research (CDER), Cervantes-Villagrana, Champion, Champion, Ciornei, Cohen, Corrales-Garcia, Courvalin, Diel, Directorate-General of the European Comission, Duplantier, Durr, Eckert, Ernst, European Commission, European Commission, European Commission, European Medicines Agency, Fattorini, Florence, Food and Drug Administration (FDA), Food and Drug Administration (FDA), Fox, Fox, Fox, Francisco Miguel Gama, Fratti, Fuertes, Gaspar, Gelperina, Ghobrial, Giehl, Giuliani, Gler, Global Alliance for TB Drug Development, Global Drug Facility, Goldstein, Gottler, Guirado, Gunther, Hancock, Hancock, Harper, Harris, Hmama, Horn, Hunter, International Conference on Harmonizarion Expert Working Group, Ishizaki, Islam, Jarlier, Jena, Jiang, Jin, João P. Silva, Kalita, Kaplan, Kapoor, Kaspar, Kayser, Khara, Kik, Kisich, Kusnadi, Kwok, Lan, Lax, Lax, Lee, Lee, Lehrer, Levy, Li, Li, Li, Limoli, Linde, Lunov, Makarov, Mansour, Mariappan, Marr, Matsuzaki, Matsuzaki, McGhan, Miller-Keane, Mily, Miteva, Mohanty, Molhoek, Mukherjee, Mygind, Médecins sans Frontières (MSF), Nagaoka, Nawrocki, Neyrolles, Nikonenko, Nizet, Nizet, Onyebujoh, Oren, Orme, Otvos, Padhi, Pandey, Pandey, Park, Patrzykat, Peschel, Peschel, Pethe, Pietiainen, Pokorny, Prideaux, Protopopova, Ramon-Garcia, Ramos, Ramos, Rathinakumar, Rivas-Santiago, Rivas-Santiago, Rivas-Santiago, Rosenfeld, Roy, Rubinchik, Rui Appelberg, Rutherfurd, Sanborn, Santos, Santos, Saravolatz, Schatz, Scheinpflug, Sensi, Shai, Shai, Sharma, Sharma, Shaw, Sherman, Shinnar, Silva, Somoskovi, Sosnik, Sosunov, Stehr, Steinstraesser, Stenger, Sterling, Sundararajan, Swietlow, Tabata, Tahlan, Tasneen, Tomioka, Toro, Torres-Juarez, Transparency Market Research, Uhlig, van der Does, Vilcheze, Vlieghe, Wallis, Wang, Wang, Welsh, Wenzel, Wiedemann, Wimley, World Health Organization, World Health Organization (WHO), World Health Organization (WHO), World Health Organization (WHO), World Health Organization (WHO), Xiong, Yamasaki, Yang, Yeaman, Zasloff, Zasloff, Zeitler, Zelezetsky, Zhang, Zhao, Zumla, Zumla, Zumla   +208 more
core   +1 more source

Management of multidrug-resistant TB : novel treatments and their expansion to low resource settings [PDF]

, 2016
This article received no specific funding. JL is supported by the Wellcome Trust as a clinical PhD fellow [grant number 109105/Z/15/Z].Despite overall progress in global TB control, the rising burden ofmultidrug-resistant TB (MDR-TB) threatens to ...
Lewis, Joseph M., Sloan, Derek James
core   +2 more sources

Treatment of Highly Drug-Resistant Pulmonary Tuberculosis [PDF]

, 2020
BACKGROUND Patients with highly drug-resistant forms of tuberculosis have limited treatment options and historically have had poor outcomes. METHODS In an open-label, single-group study in which follow-up is ongoing at three South African sites, we ...
Akkerman, Onno W, Bolhuis, Mathieu S, van der Werf, Tjip S   +2 more
core   +1 more source

Chiral Capillary Electrokinetic Chromatography: Principle and Applications, Detection and Identification, Design of Experiment, and Exploration of Chiral Recognition Using Molecular Modeling [PDF]

, 2021
This work reviews the literature of chiral capillary electrokinetic chromatography from January 2016 to March 2021. This is done to explore the state-of-the-art approach and recent developments carried out in this field.
Borges, Keyller Bastos, El Deeb, Sami, Hanafi, Rasha Sayed, Junior, Clebio Soares Nascimento, Silva, Camilla Fonseca   +4 more
core   +1 more source

Estimated generic prices for novel treatments for drug resistant tuberculosis [PDF]

, 2016
Background: Estimated annual incidence of MDR-TB is 480,000, representing 5% of TB incidence, but 20% of mortality. Multiple drugs have recently been developed or re-purposed for the treatment of MDR-TB. Currently, treatment for MDR-TB costs thousands of
Cooke, GS, Fortunak, J, Gotham, D, Hill, A, Khoo, S, Nytko, F, Pozniak, A   +6 more
core   +1 more source

Fighting tuberculosis by drugs targeting nonreplicating Mycobacterium tuberculosis bacilli

International Journal of Mycobacteriology, 2017
Current tuberculosis (TB) treatment requires 6 months of combination therapy with isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and ethambutol for active TB and 9 months of INH or 3 months of rifapentine (RFP) + INH for latent TB.
Angelo Iacobino, Giovanni Piccaro, Federico Giannoni, Alessandro Mustazzolu, Lanfranco Fattorini   +4 more
doaj   +1 more source

New Topoisomerase Inhibitors:Evaluating the Potency of Gepotidacin and Zoliflodacin in Fluoroquinolone-Resistant Escherichia coli upon tolC Inactivation and Differentiating Their Efflux Pump Substrate Nature [PDF]

, 2021
Inactivating tolC in multidrug-resistant Escherichia coli with differing sequence types and quinolone resistance-determining mutations reveals remarkably potentiated activity of the first-in-class topoisomerase inhibitors gepotidacin and zoliflodacin ...
Kern, Winfried V, Köser, Raphael, Rossen, John W A, Schuster, Sabine, Vavra, Martina   +4 more
core   +1 more source